U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Erlotinib response

MedGen UID:
450453
•Concept ID:
CN077981
•
Sign or Symptom
Synonym: Tarceva response
Drug:
Erlotinib
MedGen UID:
209555
•Concept ID:
C1135135
•
Pharmacologic Substance
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. [from NCI]
Erlotinib

Professional guidelines

PubMed

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.
Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, Tarsia P, Cattelan A, Comes A, De Laurentiis M, Falcone A, Regge D, Richeldi L, Siena S
ESMO Open 2022 Apr;7(2):100404. Epub 2022 Feb 24 doi: 10.1016/j.esmoop.2022.100404. PMID: 35219244Free PMC Article
Overview of current systemic management of EGFR-mutant NSCLC.
Hsu WH, Yang JC, Mok TS, Loong HH
Ann Oncol 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702. PMID: 29462253
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Curated

DailyMed Drug Label, TARCEVA, 2014

Recent clinical studies

Etiology

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH
J Oncol Pharm Pract 2021 Oct;27(7):1665-1673. Epub 2020 Oct 12 doi: 10.1177/1078155220964895. PMID: 33040673
Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.
Tu C, Pi Y, Xing S, Ling Y
PLoS One 2020;15(10):e0240633. Epub 2020 Oct 19 doi: 10.1371/journal.pone.0240633. PMID: 33075110Free PMC Article
Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
López-Ayllón BD, de Castro-Carpeño J, Rodriguez C, Pernía O, Ibañez de Cáceres I, Belda-Iniesta C, Perona R, Sastre L
Int J Clin Exp Pathol 2015;8(3):2888-98. Epub 2015 Mar 1 PMID: 26045797Free PMC Article
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G
Neoplasia 2011 Nov;13(11):1026-34. doi: 10.1593/neo.111016. PMID: 22131878Free PMC Article

Diagnosis

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA, Ebert EBF, Clement MS, Winther-Larsen A, Meldgaard P, Sorensen B
Lung Cancer 2019 Sep;135:92-96. Epub 2019 Jul 12 doi: 10.1016/j.lungcan.2019.07.005. PMID: 31447008
miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.
Zhang W, Lin J, Wang P, Sun J
J Drug Target 2017 Feb;25(2):125-131. Epub 2016 Sep 16 doi: 10.1080/1061186X.2016.1207647. PMID: 27633093
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR
JAMA Oncol 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34. PMID: 26181029Free PMC Article
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR
Clin Cancer Res 2013 Jan 15;19(2):380-92. Epub 2012 Dec 4 doi: 10.1158/1078-0432.CCR-12-1555. PMID: 23213056Free PMC Article
Clinical experience with erlotinib in non-small-cell lung cancer.
Felip E, Rosell R
Drugs Today (Barc) 2006 Mar;42(3):147-56. doi: 10.1358/dot.2006.42.3.957358. PMID: 16628257

Therapy

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH
J Oncol Pharm Pract 2021 Oct;27(7):1665-1673. Epub 2020 Oct 12 doi: 10.1177/1078155220964895. PMID: 33040673
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR
JAMA Oncol 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34. PMID: 26181029Free PMC Article
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR
Clin Cancer Res 2013 Jan 15;19(2):380-92. Epub 2012 Dec 4 doi: 10.1158/1078-0432.CCR-12-1555. PMID: 23213056Free PMC Article
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G
Neoplasia 2011 Nov;13(11):1026-34. doi: 10.1593/neo.111016. PMID: 22131878Free PMC Article
Clinical experience with erlotinib in non-small-cell lung cancer.
Felip E, Rosell R
Drugs Today (Barc) 2006 Mar;42(3):147-56. doi: 10.1358/dot.2006.42.3.957358. PMID: 16628257

Prognosis

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH
J Oncol Pharm Pract 2021 Oct;27(7):1665-1673. Epub 2020 Oct 12 doi: 10.1177/1078155220964895. PMID: 33040673
Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA, Ebert EBF, Clement MS, Winther-Larsen A, Meldgaard P, Sorensen B
Lung Cancer 2019 Sep;135:92-96. Epub 2019 Jul 12 doi: 10.1016/j.lungcan.2019.07.005. PMID: 31447008
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR
JAMA Oncol 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34. PMID: 26181029Free PMC Article
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, Farrell M, Amberger-Murphy V
Exp Cell Res 2012 Mar 10;318(5):641-52. Epub 2012 Jan 20 doi: 10.1016/j.yexcr.2012.01.014. PMID: 22285130
Clinical experience with erlotinib in non-small-cell lung cancer.
Felip E, Rosell R
Drugs Today (Barc) 2006 Mar;42(3):147-56. doi: 10.1358/dot.2006.42.3.957358. PMID: 16628257

Clinical prediction guides

Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH
J Oncol Pharm Pract 2021 Oct;27(7):1665-1673. Epub 2020 Oct 12 doi: 10.1177/1078155220964895. PMID: 33040673
Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA, Ebert EBF, Clement MS, Winther-Larsen A, Meldgaard P, Sorensen B
Lung Cancer 2019 Sep;135:92-96. Epub 2019 Jul 12 doi: 10.1016/j.lungcan.2019.07.005. PMID: 31447008
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR
JAMA Oncol 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34. PMID: 26181029Free PMC Article
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G
Neoplasia 2011 Nov;13(11):1026-34. doi: 10.1593/neo.111016. PMID: 22131878Free PMC Article
Clinical experience with erlotinib in non-small-cell lung cancer.
Felip E, Rosell R
Drugs Today (Barc) 2006 Mar;42(3):147-56. doi: 10.1358/dot.2006.42.3.957358. PMID: 16628257

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Consumer resources

    Reviews

    Related information

    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...